SCHEMBL6355870

SCHEMBL6355870

CC(C)C(C(=O)O)N(CC(=O)c1ccccc1)C(=O)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
LMNA P02545 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
POLB P06746 1/20 0.48
HSD17B10 Q99714 1/20 0.48
KMT2A Q03164 2/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A3 Q01959 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
SLC15A1 P46059 1/20 0.40
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ABCB1 P08183 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20721731 0.92 ALDH1A1 (0.48) ALDH1A1LMNAL3MBTL1POLBHSD17B10
SCHEMBL6356582 0.91 SLC6A2 (0.43) ALDH1A1LMNAL3MBTL1POLBHSD17B10
SCHEMBL7616932 0.88 ALDH1A1 (0.51) ALDH1A1LMNAL3MBTL1POLBHSD17B10
SCHEMBL6354396 0.87 ALDH1A1 (0.57) ALDH1A1LMNAL3MBTL1POLBHSD17B10
SCHEMBL6350485 0.84 KMT2A (0.44) ALDH1A1LMNAL3MBTL1POLBHSD17B10
SCHEMBL22122326 0.84 ALDH1A1 (0.56) ALDH1A1LMNAL3MBTL1POLBHSD17B10
SCHEMBL22122328 0.84 ALDH1A1 (0.56) ALDH1A1LMNAL3MBTL1POLBHSD17B10
SCHEMBL6357950 0.80 ALDH1A1 (0.48) ALDH1A1LMNAL3MBTL1POLBHSD17B10
SCHEMBL6349361 0.79 ALDH1A1 (0.45) ALDH1A1LMNAL3MBTL1KMT2ATDP1
SCHEMBL6358298 0.79 TSHR (0.42) ALDH1A1LMNAL3MBTL1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 ALDH1A1 420/4885LMNA 3734/4885L3MBTL1 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.